Morgan Stanley
-
-
-
-
-
-
-
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
-
-
-
-
-
-
-
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
-
-
-
-
-
-
-
AbbVie to Present at the Morgan Stanley Healthcare Conference
-
-
-
-
-
-
-
Berkshire Hathaway Inc. (BRK-B) is a Net Seller in 2Q, Adds One, Liquidates Two Positions
-
-
-
-
-
-
-
Abbvie (ABBV) PT Raised to $120 at Morgan Stanley
-
-
-
-
-
-
-
U.S. dominates second quarter global M&A as mega deals roll on
-
-
-
-
-
-
-
Abbvie (ABBV) PT Lowered to $100 at Morgan Stanley
-
220,211 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

